Nephro Care India Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2025 • OPD Services: 51.8% • Sale of Medicines From Pharmacy: 25.1% • IPD Services: 23.4%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company has a good return on equity (ROE) track record: 3 Years ROE 72.9%
- Company has a healthy return on capital (ROCE) of 47.7%
- Operating margins have improved to 12.8% from 3.7%
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.22x)
CONS
- Receivables are growing faster than sales - a possible quality concern
- A large part of profit comes from other income (31.6% of PBT)
- Working capital days have increased from 68 to 113 days
- Rich enterprise valuation - EV/EBITDA of 27.7x
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | 8715.00 | 59.97 | 125308.33 | 0.23 | 610.40 | 38.41 | 7043.50 | 20.56 | 21.73 | 15.70 |
| MAXHEALTH | 994.00 | 66.40 | 96743.68 | 0.20 | 322.96 | 4.87 | 2366.17 | 16.70 | 14.97 | 25.29 |
| MANIPALHOS | 709.15 | 104.54 | 93279.97 | 0.00 | 2434.30 | — | 30906.30 | — | 13.93 | 23.83 |
| FORTIS | 913.85 | 65.84 | 68991.85 | 0.11 | 272.80 | 2.26 | 2545.03 | 17.46 | 14.07 | 21.28 |
| ASTERDM | 762.10 | 208.45 | 66430.16 | 0.00 | 29.28 | -68.70 | 1310.68 | 21.60 | 11.46 | 19.53 |
| NH | 1922.95 | 48.15 | 39297.56 | 0.23 | 207.27 | 5.37 | 2683.63 | 78.05 | 16.20 | 17.43 |
| MEDANTA | 1445.50 | 69.88 | 38865.42 | 0.03 | 157.25 | -1.09 | 1304.05 | 26.50 | 19.38 | 21.99 |
| LALPATHLAB | 1913.55 | 59.27 | 32118.71 | 1.07 | 1705.00 | 1172.39 | 7977.00 | 1090.95 | 29.56 | 31.03 |
| KIMS | 753.40 | 154.89 | 31643.29 | 0.00 | 37.40 | -56.00 | 1179.50 | 35.33 | 11.51 | 19.03 |
| AGARWALEYE | 513.40 | 109.70 | 16276.12 | 0.00 | 55.02 | 44.56 | 614.02 | 25.97 | 16.14 | 27.75 |
| VIJAYA | 1480.70 | 81.34 | 15250.87 | 0.14 | 53.10 | 37.61 | 230.98 | 22.83 | 30.28 | 42.66 |
| NEPHROCARE | 101.85 | 47.47 | 167.91 | 0.00 | 16.08 | — | 291.85 | — | 14.42 | 12.39 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| 17 | 23 | 27 | 29 | |
| 18 | 21 | 25 | 27 | |
| Operating Profit | 1 | 2 | 2 | 4 |
| OPM % | 3.47% | 8.43% | 7.55% | 12.39% |
| Other Income | 0 | 0 | 1 | 0 |
| Interest | 0 | 0 | -0 | 0 |
| Depreciation | 1 | 1 | 2 | 1 |
| -1 | 1 | 1 | 3 | |
| Tax % | -0.00% | 25.00% | 22.31% | 38.45% |
| Net Profit | -1 | 0 | 1 | 2 |
| 0 | 0 | 1 | 0 | |
| Equity Capital | 16 | 16 | 16 | 16 |
| Reserves | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 2 | 3 | 17 | 27 | 46 | 96 | |
| 2 | 3 | 14 | 21 | 40 | 90 | |
| Operating Profit | 0 | 0 | 3 | 7 | 7 | — |
| OPM % | 9 | 4 | 20 | 25 | 16 | — |
| Other Income | 0 | 0 | 0 | 0 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 1 | 2 | 5 |
| 0 | 0 | 3 | 6 | 5 | 4 | |
| Tax % | 25 | 5,000 | 8 | 28 | 25 | 38 |
| Net Profit | 0 | -0 | 2 | 5 | 4 | 2 |
| EPS | 4 | -0 | 2 | 4 | 2 | — |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | — |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 4 | -0 | 2 | 4 | 2 | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 138%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- -40%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 161%
- 3 Years:
- 73%
- Last Year:
- 11%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| LIABILITIES | - | - | - | - | - |
| Equity Capital | 0 | 0 | 0 | 12 | 16 |
| 0 | -0 | 2 | 3 | 37 | |
| Trade Payables | 0 | 0 | 1 | 2 | 4 |
| 1 | 4 | 5 | 4 | 11 | |
| Total Liabilities | 1 | 5 | 8 | 21 | 68 |
| ASSETS | - | - | - | - | - |
| 0 | 1 | 3 | 5 | 31 | |
| Capital Work in Progress | 0 | 2 | 0 | 1 | 1 |
| 0 | 0 | 2 | 7 | 19 | |
| 0 | 0 | 0 | 0 | 1 | |
| 0 | 0 | 0 | 0 | 3 | |
| Cash & Bank | 0 | 1 | 2 | 1 | 5 |
| 0 | 1 | 0 | 7 | 9 | |
| Total Assets | 1 | 5 | 8 | 21 | 68 |
| Total Debt | 1 | 3 | 2 | 0 | 0 |
| Net Working Capital | 0 | -1 | -0 | 5 | 14 |
| Contingent Liabilities | 0 | 0 | 0 | 0 | 0 |
| Book Value per Share | 15.00 | 9.90 | 50.57 | 12.62 | 32.44 |
| Face Value | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 0 | 1 | 4 | 1 | 8 | |
| Cash from Investing | -0 | -3 | -2 | -8 | -40 |
| Cash from Financing | 0 | 2 | -0 | 6 | 35 |
| 0 | 0 | 2 | -1 | 3 | |
| Free Cash Flow | 0 | -2 | 4 | -2 | -21 |
| OCF / Net Profit | 2.56 | -62.99 | 1.74 | 0.20 | 2.15 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| PER SHARE | |||||
| EPS (₹) | 88.70 | -0.20 | 47.45 | 3.78 | 2.21 |
| Book Value (₹) | 15.00 | 9.90 | 50.57 | 12.62 | 32.44 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 5.08 | 0.10 | 3.16 | 4.23 | 3.70 |
| PROFITABILITY | |||||
| Operating Margin % | 8.90% | 3.74% | 20.05% | 23.75% | 12.76% |
| Net Margin % | 4.86% | -0.29% | 13.88% | 16.53% | 7.91% |
| ROE % | 591.33% | -3.84% | 156.92% | 51.30% | 10.62% |
| ROCE % | 21.11% | 0.90% | 65.72% | 62.97% | 14.42% |
| 7.88% | -0.34% | 37.08% | 31.00% | 8.16% | |
| EFFICIENCY | |||||
| Debtor Days | 0 | 21 | 3 | 1 | 13 |
| Inventory Days | 5 | 10 | 7 | 6 | 6 |
| Payable Days | 94 | 96 | 51 | 57 | 80 |
| -89 | -65 | -42 | -50 | -60 | |
| FINANCIAL HEALTH | |||||
| Debt to Equity (x) | 46.18x | 5.12x | 0.98x | 0.00x | 0.00x |
| Interest Coverage (x) | 4.74x | 1.01x | 40.23x | 74.13x | 44.86x |
| 1.08x | 0.66x | 0.89x | 1.86x | 2.01x | |
| GROWTH | |||||
| Revenue Growth % | 0.00% | 87.66% | 399.14% | 59.31% | 69.04% |
| Operating Profit Growth % | 0.00% | -21.06% | 2573.32% | 99.47% | 8.24% |
| Net Profit Growth % | 0.00% | -111.05% | 0.00% | 89.77% | -19.18% |
| 0.00% | 0.00% | 0.00% | -92.03% | -41.65% | |
| VALUATION | |||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 57.61x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 3.92x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 0.00x | 1.55x | 27.70x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for NEPHROCARE
Loading news…
AI Stock Analyst
Nephro Care India Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account